EX-23.2 6 axsm-ex23_2.htm CONSENT OF ERNST & YOUNG LLP EX-23.2

 

Exhibit 23.2

 

Consent of Independent Registered Public Accounting Firm

 

We consent to the incorporation by reference in the Registration Statements on:

 

Form S-8 (No. 333-217002);
Form S-8 (No. 333-208579);
Form S-8 (No. 333-230296);
Form S-8 (No. 333-226824);
Form S-8 (No. 333-238174);
Form S-8 (No. 333-256019);
Form S-8 (No. 333-264621);
Form S-8 (No. 333-271741);
Form S-8 (No. 333-272891); and
Form S-3 (No. 333-268664).

 

of our reports dated February 27, 2023, with respect to the consolidated financial statements of Axsome Therapeutics, Inc., included in this Annual Report (Form 10-K) of Axsome Therapeutics, Inc. for the year ended December 31, 2023.

 

 

 

/s/ Ernst & Young LLP

 

 

New York, New York

 

February 23, 2024